Carlsbad, CA – March 7, 2011 Life Technologies Corporation today announced the commercial availability of its newest advancement in capillary electrophoresis (CE) sequencing reagents with the BigDye® Direct Cycle Sequencing Kit.  The kit, to be used with the company’s portfolio of Applied Biosystems™ Genetic Analyzers, simplifies the Sanger sequencing workflow by combining post-PCR cleanup and cycle sequencing into a single step and allows reads as close as one base from the primer using POP-7™ polymer. 

“The BigDye Direct kit is easier to use and has fewer steps than other sequencing kits,” said Dr. Tetsuro Noguchi, Lead Biologist, Laboratoire d’Oncolgenetique Molecular, Institut Paoli-Calmettes, Marseille, France.  “Reducing steps in the lab helps improve sample traceability and decrease the possibility of manual errors.  We are pleased with the quality of data produced by the BigDye Direct kit, including the ability to obtain good sequence calls close to the primer.”

By combining several steps in the sequencing protocol, the BigDye Direct Cycle Sequencing Kit decreases overall workflow time from sample preparation to results, providing time savings for researchers who are performing resequencing applications.  The kit’s ease-of-use ensures better reproducibility, less chance of error and can reduce training time for users.

“Life Technologies recognizes that CE-based sequencing remains a critical tool in genomic analysis laboratories and the launch of the BigDye Direct Cycle Sequencing Kit demonstrates our continued commitment to supporting this platform,” said Todd Laird, General Manager and head of the Fragment and Sequence Genomics division for Life Technologies.  “Sanger sequencing is the gold standard technology for DNA sequence analysis.  Therefore, CE continues to be an ideal platform for routine analysis of DNA biomarkers, including SNPs, STRs, and other types of genetic variants, and is increasingly used in confirming results from next generation sequencing platforms.”

For more information, visit

About Life Technologies Next-Generation Sequencing

Life Technologies is the world’s leading provider of sequencing technologies, offering the industry’s gold standard capillary electrophoresis technology with the 3500 CE and 3500Dx Series Genetic Analyzers, next-generation sequencing technology with the SOLiD System, and the semiconductor-based sequencing technology with the recently launched Ion Torrent PGM.  

The 3500 CE and 3500Dx Series Genetic Analyzers are for research use only.

About Life Technologies

Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition.  Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better.  Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics.  The company manufactures both molecular diagnostic and research use only products.  Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, Gibco, Ambion, Molecular Probes and Taqman products.  Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses.  For more information on how we are making a difference, please visit our website:  Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Life Technologies’ Safe Harbor Statement

This press release includes forward-looking statements about Life Technologies’ anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies Contact

Patty Zamora